Stay updated with the latest stock market news and insights
Weekly insights + SMS alerts
So, Clearmind Medicine Inc. (CMND) shares are taking a little dip on Wednesday morning. Think of it as the stock catching its breath after sprinting a marathon. It's undergoing a classic price correction following what can only be described as a massive two-day rally.
On Monday, the ticker absolutely skyrocketed, gaining over 100% and hitting highs near $1.52. That's the kind of move that gets everyone's attention.
The initial rocket fuel came from positive Phase I/IIa clinical trial results for CMND-100, the company's drug candidate targeting Alcohol Use Disorder (AUD). Clearmind reported that the treatment met its primary safety and tolerability endpoints. The third cohort, in particular, showed a strong safety profile with no serious adverse events, even at the highest tested doses. That's the good stuff biotech investors look for.
Adding another layer to the story, the company publicly commended President Donald Trump's executive order from this past Saturday. The order directs the U.S. Food and Drug Administration (FDA) to prioritize breakthrough psychedelic therapies. For a company like Clearmind working in this space, that's not just a footnote—it's a potential historic catalyst that could smooth the regulatory path forward.
Now, let's look at the chart. Despite the recent fireworks, Clearmind's stock remains pinned near the low end of its 52-week range, which spans from $52.40 down to 59 cents. It's currently trading 23.9% below its 20-day simple moving average and a hefty 62.8% below its 100-day SMA.
As for the latest numbers, Clearmind Medicine shares were down 9.68% at $0.74 during premarket trading on Wednesday, according to market data.
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
